{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T23:54:05Z","timestamp":1795132445552,"version":"4.10.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41591-025-03591-0","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T06:13:14Z","timestamp":1742278394000},"page":"1484-1493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1\/2 trial"],"prefix":"10.1038","volume":"31","author":[{"given":"Amanda K.","family":"Rudman Spergel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintanat","family":"Ananworanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizbeth","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Schaefers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamuna D.","family":"Paila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Kandinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles H.","family":"Eger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Sinkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0471-206X","authenticated-orcid":false,"given":"Christine A.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"3591_CR1","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"GBD 2021 Diseases and Injuries Collaborators.","year":"2024","unstructured":"GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403, 2133\u20132161 (2024).","journal-title":"Lancet"},{"key":"3591_CR2","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/S0140-6736(24)00685-8","volume":"403","author":"GBD 2021 Forecasting Collaborators.","year":"2024","unstructured":"GBD 2021 Forecasting Collaborators. Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet 403, 2204\u20132256 (2024).","journal-title":"Lancet"},{"key":"3591_CR3","first-page":"185","volume":"97","author":"World Health Organization.","year":"2022","unstructured":"World Health Organization. Vaccines against influenza: WHO position paper - May 2022. Wkly Epidemiol. Rec. 97, 185\u2013208 (2022).","journal-title":"Wkly Epidemiol. Rec."},{"key":"3591_CR4","unstructured":"Havers, F. P. COVID-19-Associated Hospitalizations Among Infants, Children and Adults COVID NET, January\u2013August 2023 (Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, 2023)."},{"key":"3591_CR5","unstructured":"RESP-NET interactive dashboard (2023\u201324 season). CDC www.cdc.gov\/resp-net\/dashboard\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/surveillance\/resp-net\/dashboard.html (2024)."},{"key":"3591_CR6","unstructured":"FluView interactive: pneumonia and influenza mortality surveillance from the National Center for Health Statistics Mortality Surveillance System. CDC https:\/\/gis.cdc.gov\/grasp\/fluview\/mortality.html (2024)."},{"key":"3591_CR7","unstructured":"Trends in United States COVID-19 deaths, emergency department (ED) visits, and test positivity by geographic area. CDC https:\/\/covid.cdc.gov\/covid-data-tracker\/#trends_totaldeaths_select_00 (2024)."},{"key":"3591_CR8","unstructured":"Immunization overview for fall and winter 2023\u20132024. CDC www.cdc.gov\/ncird\/whats-new\/immunization-overview-2023-2024.html (2023)."},{"key":"3591_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss7003a1","volume":"70","author":"PJ Lu","year":"2021","unstructured":"Lu, P. J. et al. Surveillance of vaccination coverage among adult populations\u2014United States, 2018. MMWR Surveill. Summ. 70, 1\u201326 (2021).","journal-title":"MMWR Surveill. Summ."},{"key":"3591_CR10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/vaccines12020216","volume":"12","author":"RCA Achterbergh","year":"2024","unstructured":"Achterbergh, R. C. A., McGovern, I. & Haag, M. Co-administration of influenza and COVID-19 vaccines: policy review and vaccination coverage trends in the European Union, UK, US, and Canada between 2019 and 2023. Vaccines (Basel) 12, 216 (2024).","journal-title":"Vaccines (Basel)"},{"key":"3591_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3390\/vaccines11030517","volume":"11","author":"N Bergen","year":"2023","unstructured":"Bergen, N., Johns, N. E., Chang Blanc, D. & Hosseinpoor, A. R. Within-country inequality in COVID-19 vaccination coverage: a scoping review of academic literature. Vaccines (Basel) 11, 517 (2023).","journal-title":"Vaccines (Basel)"},{"key":"3591_CR12","unstructured":"Flu vaccination dashboard (2023-24 season). CDC Last updated 24 May 2024 https:\/\/www.cdc.gov\/flu\/fluvaxview\/dashboard\/vaccination-dashboard.html#print (2024)."},{"key":"3591_CR13","unstructured":"COVID-19 vaccination dashboard (2023-24 season). CDC Last updated 22 May 2024 https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/covidvaxview\/interactive\/vaccination-dashboard.html#print (2024)."},{"key":"3591_CR14","unstructured":"Interim Recommendations for the Use of mRNA COVID-19 Vaccines (World Health Organization, 2023); https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccines-SAGE-recommendation-mRNA-2023.1"},{"key":"3591_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2195786","volume":"19","author":"P Bonanni","year":"2023","unstructured":"Bonanni, P. et al. Vaccine co-administration in adults: an effective way to improve vaccination coverage. Hum. Vaccin. Immunother. 19, 2195786 (2023).","journal-title":"Hum. Vaccin. Immunother."},{"key":"3591_CR16","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","volume":"36","author":"S John","year":"2018","unstructured":"John, S. et al. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine 36, 1689\u20131699 (2018).","journal-title":"Vaccine"},{"key":"3591_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39376-7","volume":"14","author":"IT Lee","year":"2023","unstructured":"Lee, I. T. et al. Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis. Nat. Commun. 14, 3631 (2023).","journal-title":"Nat. Commun."},{"key":"3591_CR18","doi-asserted-by":"publisher","first-page":"126847","DOI":"10.1016\/j.vaccine.2025.126847","volume":"50","author":"M Soens","year":"2025","unstructured":"Soens, M. et al. A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults. Vaccine 50, 126847 (2025).","journal-title":"Vaccine"},{"key":"3591_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf4100","volume":"15","author":"GBE Stewart-Jones","year":"2023","unstructured":"Stewart-Jones, G. B. E. et al. Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2. Sci. Transl. Med. 15, eadf4100 (2023).","journal-title":"Sci. Transl. Med."},{"key":"3591_CR20","unstructured":"Vaccines and Business Updates (Moderna, 2024); https:\/\/s29.q4cdn.com\/435878511\/files\/doc_events\/2024\/Mar\/27\/vaccines-day-2024_final_for-pdf_040224.pdf"},{"key":"3591_CR21","unstructured":"Moderna announces positive phase 3 efficacy data for mRNA-1283, the company\u2019s next generation COVID-19 vaccine. Moderna https:\/\/news.modernatx.com\/news\/news-details\/2024\/Moderna-Announces-Positive-Phase-3-Efficacy-Data-for-mRNA-1283-the-Companys-Next-Generation-COVID-19-Vaccine\/default.aspx (2024)."},{"key":"3591_CR22","unstructured":"Third Quarter 2023 Earnings Teleconference (Pfizer, 2023); https:\/\/s28.q4cdn.com\/781576035\/files\/doc_financials\/2023\/q3\/Q3-2023-Earnings-Charts-FINAL.pdf"},{"key":"3591_CR23","unstructured":"CIC, Stand-alone influenza, and high-dose COVID-19 vaccine candidates (Novavax, 2023); https:\/\/novavax.widen.net\/s\/7rdlpxq9zl\/nvax-clinical-presentation-cic-flu-high-dose-december-2023-final"},{"key":"3591_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02321-z","volume":"11","author":"V Rotshild","year":"2021","unstructured":"Rotshild, V., Hirsh-Raccah, B., Miskin, I., Muszkat, M. & Matok, I. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci. Rep. 11, 22777 (2021).","journal-title":"Sci. Rep."},{"key":"3591_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.15585\/mmwr.mm7304a2","volume":"73","author":"R Link-Gelles","year":"2024","unstructured":"Link-Gelles, R. et al. Early estimates of updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating omicron variants among immunocompetent adults - increasing community access to testing program, United States, September 2023\u2013January 2024. MMWR Morb. Mortal. Wkly Rep. 73, 77\u201383 (2024).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"3591_CR26","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJMc2215471","volume":"388","author":"DY Lin","year":"2023","unstructured":"Lin, D. Y. et al. Effectiveness of bivalent boosters against severe omicron infection. N. Engl. J. Med. 388, 764\u2013766 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3591_CR27","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1016\/S1473-3099(24)00150-6","volume":"24","author":"DY Lin","year":"2024","unstructured":"Lin, D. Y., Huang, S., Milinovich, A., Duggal, A. & Wang, X. Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA. Lancet Infect. Dis. 24, e278\u2013e280 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"3591_CR28","volume":"6","author":"KJ Bruxvoort","year":"2022","unstructured":"Bruxvoort, K. J. et al. Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study. Lancet Reg. Health Am. 6, 100134 (2022).","journal-title":"Lancet Reg. Health Am."},{"key":"3591_CR29","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/d41573-021-00176-7","volume":"20","author":"E Dolgin","year":"2021","unstructured":"Dolgin, E. mRNA flu shots move into trials. Nat. Rev. Drug Discov. 20, 801\u2013803 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3591_CR30","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00838-21","volume":"12","author":"JJ Guthmiller","year":"2021","unstructured":"Guthmiller, J. J. et al. An egg-derived sulfated N-acetyllactosamine glycan is an antigenic decoy of influenza virus vaccines. mBio 12, e0083821 (2021).","journal-title":"mBio"},{"key":"3591_CR31","unstructured":"Fluarix Quadrivalent (Influenza Vaccine) injectable suspension, for intramuscular use\u20142023\u20132024. Formula prescribing information (GlaxoSmithKline, 2023); https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Fluarix_Quadrivalent\/pdf\/FLUARIX-QUADRIVALENT.PDF"},{"key":"3591_CR32","unstructured":"Fluzone\u00ae high-dose quadrivalent (influenza vaccine), suspension, for intramuscular injection\u20142023\u20132024. Formula prescribing information (Sanofi Pasteur Inc., 2023); www.fffenterprises.com\/assets\/downloads\/product-information\/sanofi-pasteur\/pi-FLUZONE-HIGH-DOSE_2023-24.pdf"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03591-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03591-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03591-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T10:57:50Z","timestamp":1747738670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03591-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3591"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03591-0","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.K.R.S., J.A., R.G., W.D., L.C., K.S., Y.D.P., B.K., M.S., S.S., C.H. and C.A.S. are employees of Moderna, Inc., and may hold stock\/stock options in the company. The remaining author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}